For the Inventor, By the Inventor

Enter assignee name

Bridgewater, NJ, United States of America

Enzon Pharmaceuticals, Inc.

USPTO Granted Patents = 52

% Expired Patents = 90.4

EPO Patents = 5

Trademarks = 1

Forward Citations = 766

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Hong Zhao (25 out of 36 patents)

Richard B Greenwald (11 out of 61 patents)

Charlotte Albaek Thrue (8 out of 19 patents)

4. Majken Westergaard (7 out of 17 patents)

5. Puja Sapra (6 out of 7 patents)

6. Dechun Wu (5 out of 8 patents)

7. Jesper Worm (5 out of 10 patents)

8. Paul E G Kristjansen (4 out of 6 patents)

9. Maria Belen Rubio (4 out of 4 patents)

10. Margit Wissenbach (4 out of 4 patents)

11. Belen Rubio (4 out of 4 patents)

12. Frank Winther Rasmussen (3 out of 58 patents)

13. Henrik Frydenlund Hansen (3 out of 32 patents)

14. Anja Molhart Hog (3 out of 4 patents)

15. Susan L Adler, Legal Representative (3 out of 3 patents)

Core Competencies:

LNA Oligonucleotides

Polymeric Conjugates

Cancer Treatment

HIF-1A Expression

Biodegradable Linkers

RNA Antagonists

Multifunctional Linkers

Prodrugs

Androgen Receptor

Survivin Expression

Beta-Catenin

PIK3CA Expression

52 patents: Sort by Forward Citations

1. 9506060 - LNA antisense oligonucleotides for the modulation of Myc expression (2016-11-29),

2. 8450290 - Methods for treating androgen receptor dependent disorders including cancers (2013-05-28),

3. 8410071 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2013-04-02),

4. 8367065 - Targeted polymeric prodrugs containing multifunctional linkers (2013-02-05),

5. 8357670 - Oligomeric compounds for the modulation of HIF-1A expression (2013-01-22),

6. 8299089 - Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers (2012-10-30),

7. 8268793 - RNA antagonist compounds for the modulation of HER3 (2012-09-18),

8. 8268318 - Polyalkylene oxides having hindered ester-based biodegradable linkers (2012-09-18),

9. 8207140 - Oligomeric compounds for the modulation of HIF-1α expression (2012-06-26),

10. 8192743 - Releasable polymeric conjugates based on aliphatic biodegradable linkers (2012-06-05),

11. 8173428 - LNA oligonucleotides and the treatment of cancer (2012-05-08),

12. 8168605 - Polymeric oligonucleotide prodrugs (2012-05-01),

13. 8133707 - Methods of preparing activated polymers having alpha nitrogen groups (2012-03-13),

14. 8110559 - Hindered ester-based biodegradable linkers for oligonucleotide delivery (2012-02-07),

15. 8048891 - Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin (2011-11-01),

Company Overview

Enzon Pharmaceuticals, Inc., based in Bridgewater, NJ, specializes in innovative polymeric drug delivery systems aimed at enhancing therapeutic efficacy. The company focuses on developing LNA oligonucleotides and polymeric conjugates, particularly for cancer treatment. Enzon's research encompasses advanced technologies such as biodegradable linkers and multifunctional linkers, which facilitate the delivery of RNA antagonists and prodrugs. Their commitment to improving patient outcomes through targeted therapies positions them as a key player in the pharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

52 Patents

#7 in Bridgewater, NJ

#275 in New Jersey

#6,764 in US

#13,555 in the World

Bridgewater, NJ, United States of America

Enzon Pharmaceuticals, Inc.

Forward Citations = 766

43 inventors:

Hong Zhao (25 out of 36 patents)

Richard B Greenwald (11 out of 61 patents)

Charlotte Albaek Thrue (8 out of 19 patents)

4. Majken Westergaard (7 out of 17 patents)

5. Puja Sapra (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Enzon Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/enzon-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…